UG Healthcare Corporation (8K7) Fair Value & Analysis
Healthcare · SG · Market cap 48.7M SGD
Fair value as of: Jul 4, 2026
From 4 valuation models · updated today
Share price −8.2% over the past month.
Price vs Fair Value (12 months)
12‑month range 0.0730 SGD – 0.1100 SGD · fair‑value band 0.0250 SGD – 0.0484 SGD · the 0.0780 SGD price screens above the 0.0406 SGD fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
UG Healthcare Corporation (8K7) currently trades at 0.0780 SGD, while our model-based Fair Value estimate is 0.0406 SGD — implying the stock looks roughly 48.0% overvalued today. We read business quality at 51/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, UG Healthcare Corporation generated revenue of 146M SGD at a net margin of -3.0%. Revenue grew 2.8% year over year. It earns a return on equity of -2.5%. Net debt stands at 23.5M SGD. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
UG Healthcare Corporation Limited, an investment holding company, manufactures and sells disposable gloves. It operates through Latex Examination Gloves, Nitrile Examination Gloves, and Other Ancillary Products segments. The company distributes ancillary products, including surgical, vinyl, and cleanroom disposable gloves and reusable gloves, as well as face masks, and other medical disposables. It serves customers under the Unigloves brand name in Europe, North America, South America, Africa, Asia, and internationally. UG Healthcare Corporation Limited was founded in 1989 and is based in Singapore.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
UG Healthcare Corporation reported revenue of 144M SGD in FY2025 versus 338M SGD in FY2021, a compound −19.2%/yr. Reported net income was −3.8M SGD in FY2025.
Is 8K7 fairly valued? → Check now
Similar stocks
6 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $412.02 | $165.35 | -60% |
| EssilorLuxottica Société anonyme ESLOF | $192.00 | $126.51 | -34% |
| HOYA Corporation HOCPY | $178.46 | $103.27 | -42% |
| Medline Inc MDLN | $34.71 | $30.15 | -13% |
| Becton, Dickinson and Company BDX | $140.71 | $104.17 | -26% |
| Alcon Inc ALC | $66.58 | $36.99 | -44% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is UG Healthcare Corporation (8K7) undervalued?
What is the fair value of 8K7?
What is the quality score of 8K7?
What is the revenue of UG Healthcare Corporation (8K7)?
What is the net profit margin of 8K7?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.